Mepacrine alleviates airway hyperresponsiveness and airway inflammation in a mouse model of asthma

International Immunopharmacology

Volumn 8, Issue 6, 2008, Pages 893-899

  Ram, Arjun ^a   Mabalirajan, Ulaganathan ^a   Singh, Shashi Kant ^a   Singh, Vijay Pal ^a   Ghosh, Balaram ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

AHR; Airway inflammation; Asthma; Cysteinyl leukotrienes; Eosinophil; Mepacrine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MEPACRINE; OVALBUMIN; PEPTIDOLEUKOTRIENE; PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BAGG ALBINO MOUSE; BODY PLETHYSMOGRAPHY; CONTROLLED STUDY; DRUG DOSE INCREASE; EOSINOPHILIA; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATORY CELL; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT HYPERSENSITIVITY; RESPIRATORY TRACT INFLAMMATION; TISSUE HOMOGENATE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOCONSTRICTOR AGENTS; CYSTEINE; CYTOKINES; DISEASE MODELS, ANIMAL; EOSINOPHILS; IMMUNOGLOBULIN E; INFLAMMATION; LEUKOTRIENES; LUNG; MALE; METHACHOLINE CHLORIDE; MICE; MICE, INBRED BALB C; OVALBUMIN; PHOSPHOLIPASES A2, SECRETORY; QUINACRINE;

EID: 42649143250     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.02.005     Document Type: Article

References (34)

1. Busse W.W., and Lemanske Jr. R.F. Asthma. N Engl J Med 344 (2001) 350-362
2. Holgate S.T., Davies D.E., Puddicombe S., Richter A., Lackie P., Lordan J., et al. Mechanisms of airway epithelial damage: epithelial-mesenchymal interactions in the pathogenesis of asthma. Eur Respir J 22 (2003) 24s-29s
3. Barnes P.J., Chung K.F., and Page C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev 50 (1998) 515-596
4. Lugogo N.L., and Kraft M. Epidemiology of asthma. Clin Chest Med 27 (2006) 1-15
5. Aronson J.K. Old drugs-new uses. Br J Clin Pharmacol 64 (2007) 563-565
6. Barnes P.J. Drugs for asthma. Br J Pharmacol 147 (2006) 297-303
7. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100 (2006) 1307-1317
8. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol 110 (2002) S322-S328
9. Giembycz M.A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 5 (2005) 238-244
10. Zidovetzki R., Sherman I.W., Prudhomme J., and Crawford J. Inhibition of Plasmodium falciparum lysophospholipase by anti-malarial drugs and sulphydryl reagents. Parasitology 108 (1994) 249-255
11. Gardner T.B., and Hill D.R. Treatment of giardiasis. Clin Microbiol Rev 14 (2001) 114-128
12. Werth V. Current treatment of cutaneous lupus erythematosus. Dermatol Online J 7 (2001) 2
13. Furukawa H., Takahashi M., Nakajima M., and Yamada T. Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho 60 (2002) 1649-1657
14. Kessel E. 100,000 quinacrine sterilizations. Adv Contracept 12 (1996) 69-76
15. Engeset A. Quinacrine and chloroquine in asthma therapy. Nord Med 58 (1957) 1492-1494
16. Voog R., Chouteau J., Marchal A., and Cabanel G. Asthma therapy with a combination of synthetic antimalarials (83 cases). Presse Med 77 (1969) 1995
17. Struhar D., Kivity S., and Topilsky M. Quinacrine inhibits oxygen radicals release from human alveolar macrophages. Int J Immunopharmacol 14 (1992) 275-277
18. Vallee E., Gougat J., Navarro J., and Delahayes J.F. Anti-inflammatory and platelet anti-aggregant activity of phospholipase-A2 inhibitors. J Pharm Pharmacol 31 (1979) 588-592
19. Farooqui A.A., Litsky M.L., Farooqui T., and Horrocks L.A. Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 49 (1999) 139-153
20. Nagase T., Ishii S., Shindou H., Ouchi Y., and Shimizu T. Airway hyperresponsiveness in transgenic mice overexpressing platelet activating factor receptor is mediated by an atropine-sensitive pathway. Am J Respir Crit Care Med 165 (2002) 200-205
21. Arndt H., Russell J.B., Kurose I., Kubes P., and Granger D.N. Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis. Gastroenterology 105 (1993) 675-680
22. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G.L., Irvin C.G., et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156 (1997) 766-775
23. Ram A., Mabalirajan U., Das M., Bhattacharya I., Dinda A.K., Gangal S.V., et al. Glycyrrhizin alleviates experimental allergic asthma in mice. Int Immunopharmacol 6 (2006) 1468-1477
24. Das M., Ram A., and Ghosh B. Luteolin alleviates bronchoconstriction and airway hyperreactivity in ovalbumin sensitized mice. Inflamm Res 52 (2003) 101-106
25. 2. J Clin Invest 91 (1993) 2118-2125
26. Bisset L.R., and Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 11 (2005) 35-42
27. Vachula M., and Van Epps D.E. In vitro models of lymphocyte transendothelial migration. Invasion Metastasis 12 (1992) 66-81
28. Fish S.C., Donaldson D.D., Goldman S.J., Williams C.M., and Kasaian M.T. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 174 (2005) 7716-7724
29. Xu J., Jiang F., Nayeri F., and Zetterström O. Apoptotic eosinophils in sputum from asthmatic patients correlate negatively with levels of IL-5 and eotaxin. Respir Med 101 (2007) 1447-1454
30. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., et al. Interleukin-13: central mediator of allergic asthma. Science 282 (1998) 2258-2261
31. Kumar R.K., Herbert C., Webb D.C., Li L., and Foster P.S. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med 170 (2004) 1043-1048
32. Bowton D.L., Seeds M.C., Fasano M.B., Goldsmith B., and Bass D.A. Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Am J Respir Crit Care Med 155 (1997) 421-425
33. Scoazec J.Y., Krolak-Salmon P., Casez O., Besson G., Thobois S., Kopp N., et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol 53 (2003) 546-547
34. Barret A., Tagliavini F., Forloni G., Bate C., Salmona M., Colombo L., et al. Evaluation of quinacrine treatment for prion diseases. J Virol 77 (2003) 8462-8469